Skip to main content

Advertisement

Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Fig. 4

Soluble Aβ oligomers from other sources also inhibit hippocampal LTP. Several sources of soluble Aβ included (a) AD patient CSF; (b) APP tg mouse of AD (J20 mice); (c) cell secreted human soluble Aβ; and (d) synthetic Aβ1–42 peptide, effect on hippocampal LTP. All these impaired hippocampal LTP (red), while the inhibition of LTP by the 3 biological sources was prevented by removing soluble Aβ via immunodepletion (blue)

Back to article page